Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841744 | 0.96 | PDK1 (0.52) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL15606326 | 0.92 | PARP1 (0.57) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL30289174 | 0.92 | PARP1 (0.57) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL17153137 | 0.91 | PARP1 (0.53) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL19120482 | 0.91 | PDK1 (0.52) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL2820733 | 0.90 | PARP1 (0.55) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL20129643 | 0.90 | PARP1 (0.55) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL13681760 | 0.90 | PARP1 (0.55) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4676650 | 0.90 | PDK1 (0.54) | PARP1PDK1PDK2PDK3PDK4 | |
| SCHEMBL21528001 | 0.89 | PDK1 (0.55) | PARP1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304165-B2 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304165-B2 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1294700-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000631-A2 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | PARP1 2406/4885PDK1 3725/4885PDK2 3846/4885 |
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | PARP1 3117/4885PDK1 2664/4885PDK2 3032/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | PARP1 3383/4885PDK1 4722/4885PDK2 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.